CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth

J Biomed Biotechnol. 2012;2012:485156. doi: 10.1155/2012/485156. Epub 2012 Oct 16.

Abstract

Despite the coming of age of cancer immunotherapy, clinical benefits are still modest. An important barrier to successful cancer immunotherapy is that tumors employ a number of mechanisms to facilitate immune escape, including the production of anti-inflammatory cytokines, the recruitment of regulatory immune subsets, and the production of immunosuppressive metabolites. Significant therapeutic opportunity exists in targeting these immunosuppressive pathways. One such immunosuppressive pathway is the production of extracellular adenosine by CD73, an ectonucleotidase overexpressed in various types of cancer. We hereafter review the biology of CD73 and its role in cancer progression and metastasis. We describe the role of extracellular adenosine in promoting tumor growth through paracrine and autocrine action on tumor cells, endothelial cells, and immune cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 5'-Nucleotidase / metabolism*
  • Adenosine / metabolism*
  • Animals
  • Cell Proliferation
  • Humans
  • Neoplasms / enzymology*
  • Neoplasms / immunology
  • Neoplasms / pathology*
  • Neoplasms / therapy
  • Stromal Cells / pathology
  • T-Lymphocytes, Regulatory / immunology

Substances

  • 5'-Nucleotidase
  • Adenosine